Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,406 across all filing types
Latest filing 2024-05-13 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de
Regulatory Filings Classification · 98% confidence The document is titled 'Communiqué de presse' (Press Release) and details significant new investment plans (€1.1 billion plus previous commitments totaling €3.5 billion) by Sanofi into its French production sites (Vitry-sur-Seine, Le Trait, Lyon Gerland) for bioproduction capacity, job creation, and future drug manufacturing. This content focuses on corporate strategy, capital expenditure, and industrial development, rather than periodic financial results (ER/IR), shareholder votes (DVA), or management changes (MANG). It is a strategic announcement about capital allocation and industrial capacity expansion. This aligns best with the 'Capital/Financing Update' (CAP) category, as it explicitly details massive investment commitments for production facilities, which is a form of capital deployment/financing activity related to operations. It is not a formal regulatory filing like a 10-K or a short announcement of a report (RPA/RNS).
2024-05-13 French
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
Capital/Financing Update Classification · 95% confidence The document is explicitly titled 'Press Release' and announces a significant investment plan (€1 billion addition to €2.5 billion already committed) by Sanofi regarding biomanufacturing capacity in France. It details specific investment amounts, job creation, and future production plans. This type of announcement, focusing on corporate strategy, major capital expenditure, and operational updates, is best classified as a Capital/Financing Update (CAP) or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results. However, since the core focus is on a major industrial investment and capital commitment rather than summarizing quarterly financial performance highlights, 'CAP' is the most appropriate fit. It is not a formal regulatory filing like a 10-K, nor is it a short announcement about a report (RPA/RNS).
2024-05-13 English
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant business event: a co-exclusive licensing agreement between Sanofi and Novavax regarding a COVID-19 vaccine and combined flu/COVID-19 vaccines. It details financial terms (upfront payment, milestones, royalties) and strategic rationale. This type of announcement, detailing a major corporate transaction (licensing, partnership, potential M&A implications, or significant financing/capital structure change), is best classified as a Capital/Financing Update (CAP) if it involves substantial financial restructuring or fundraising, or potentially a Regulatory Filing (RNS) if it's a general market disclosure. However, since the core of the document is the announcement of a major licensing deal involving significant financial consideration ($1.2 billion potential) and strategic collaboration, it strongly aligns with 'Capital/Financing Update' (CAP) as it fundamentally alters the capital deployment and commercial strategy. It is not a formal regulatory report like 10-K or IR, nor is it a simple earnings release (ER) or a proxy statement (DEF 14A). Given the nature of the deal announcement, CAP is the most specific fit among the provided options for a major commercial/financial agreement.
2024-05-10 French
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Regulatory Filings Classification · 98% confidence The document is explicitly titled "Press Release" and announces a significant business event: a co-exclusive licensing agreement between Sanofi and Novavax regarding a COVID-19 vaccine and future combination vaccines. It details financial terms (upfront payment, milestones, royalties) and includes quotes from management. This structure is characteristic of an immediate public disclosure of a major corporate event, which typically falls under general Regulatory Filings (RNS) or, if it were focused purely on financial results, an Earnings Release (ER). Since it is a strategic business announcement (licensing deal, equity investment) rather than a periodic financial report (10-K, IR, ER), the most appropriate category is the general regulatory announcement fallback, RNS. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). Given the nature of the announcement, RNS is the best fit.
2024-05-10 English
6-K
Regulatory Filings
2024-05-02 English
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces new real-world data regarding the drug Beyfortus, citing publication in *The Lancet* and quoting executives from Sanofi. It details clinical efficacy results, discusses ongoing studies (NIRSE-GAL), mentions regulatory statuses (FDA Breakthrough Therapy, EMA PRIME), and provides contact information for media and investors. This format—a formal announcement of significant news, often including financial/operational updates or scientific data releases, but not being the full regulatory report itself (like 10-K or IR)—strongly indicates an Earnings Release (ER) or a general press release that functions as an initial announcement of results. Since it focuses on announcing new data and results rather than being a comprehensive quarterly report (IR) or a transcript (CT), 'ER' (Earnings Release/Initial Announcement) is the most appropriate fit, even though the content is scientific/product-focused rather than purely financial results. It serves as the initial public disclosure of this important data.
2024-05-02 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.